Treatment	B:C0087111
of	O
erythematotelangiectatic	O
rosacea	I:C1449852
with	O
the	O
fractionation	O
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
-	O
nm	O
pulsed	O
dye	I:C1289859
laser	I:C1289859
.	O

Treatment	O
of	O
erythematotelangiectatic	B:C1449852
rosacea	I:C1449852
with	O
the	O
fractionation	O
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
-	O
nm	O
pulsed	O
dye	I:C1289859
laser	I:C1289859
.	O

Treatment	O
of	O
erythematotelangiectatic	O
rosacea	I:C1449852
with	O
the	O
fractionation	B:C3161031
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
-	O
nm	O
pulsed	O
dye	I:C1289859
laser	I:C1289859
.	O

Treatment	O
of	O
erythematotelangiectatic	O
rosacea	I:C1449852
with	O
the	O
fractionation	O
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
-	O
nm	O
pulsed	B:C1289859
dye	I:C1289859
laser	I:C1289859
.	O

Various	O
lasers	O
have	O
been	O
used	O
for	O
the	O
treatment	B:C0087111
of	O
erythematotelangiectatic	O
rosacea	I:C1449852
(	O
erythematotelangiectatic	O
rosacea	I:C1449852
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	O
or	O
topical	O
therapy	I:C0150349
.	O

Various	O
lasers	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
erythematotelangiectatic	B:C1449852
rosacea	I:C1449852
(	O
erythematotelangiectatic	O
rosacea	I:C1449852
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	O
or	O
topical	O
therapy	I:C0150349
.	O

Various	O
lasers	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
erythematotelangiectatic	O
rosacea	I:C1449852
(	O
erythematotelangiectatic	B:C1449852
rosacea	I:C1449852
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	O
or	O
topical	O
therapy	I:C0150349
.	O

Various	O
lasers	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
erythematotelangiectatic	O
rosacea	I:C1449852
(	O
erythematotelangiectatic	O
rosacea	I:C1449852
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	B:C1515119
or	O
topical	O
therapy	I:C0150349
.	O

Various	O
lasers	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
erythematotelangiectatic	O
rosacea	I:C1449852
(	O
erythematotelangiectatic	O
rosacea	I:C1449852
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	O
or	O
topical	B:C0150349
therapy	I:C0150349
.	O

The	O
pulsed	B:C1289859
dye	I:C1289859
lasers	I:C1289859
(	O
pulsed	O
dye	I:C1289859
lasers	I:C1289859
)	O
are	O
an	O
effective	O
option	O
for	O
erythematotelangiectatic	O
rosacea	I:C1449852
,	O
and	O
the	O
purpuragenic	O
fluence	O
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O

The	O
pulsed	O
dye	I:C1289859
lasers	I:C1289859
(	O
pulsed	B:C1289859
dye	I:C1289859
lasers	I:C1289859
)	O
are	O
an	O
effective	O
option	O
for	O
erythematotelangiectatic	O
rosacea	I:C1449852
,	O
and	O
the	O
purpuragenic	O
fluence	O
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O

The	O
pulsed	O
dye	I:C1289859
lasers	I:C1289859
(	O
pulsed	O
dye	I:C1289859
lasers	I:C1289859
)	O
are	O
an	O
effective	O
option	O
for	O
erythematotelangiectatic	B:C1449852
rosacea	I:C1449852
,	O
and	O
the	O
purpuragenic	O
fluence	O
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O

The	O
pulsed	O
dye	I:C1289859
lasers	I:C1289859
(	O
pulsed	O
dye	I:C1289859
lasers	I:C1289859
)	O
are	O
an	O
effective	O
option	O
for	O
erythematotelangiectatic	O
rosacea	I:C1449852
,	O
and	O
the	O
purpuragenic	B:C0034150
fluence	O
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O

Given	O
that	O
purpura	B:C0034150
and	O
subsequent	O
possible	O
postinflammatory	O
hyperpigmentation	I:C0333616
(	O
postinflammatory	O
hyperpigmentation	I:C0333616
)	O
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	O
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	O
fluence	O
were	O
reported	O
.	O

Given	O
that	O
purpura	O
and	O
subsequent	O
possible	O
postinflammatory	B:C0333616
hyperpigmentation	I:C0333616
(	O
postinflammatory	O
hyperpigmentation	I:C0333616
)	O
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	O
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	O
fluence	O
were	O
reported	O
.	O

Given	O
that	O
purpura	O
and	O
subsequent	O
possible	O
postinflammatory	O
hyperpigmentation	I:C0333616
(	O
postinflammatory	B:C0333616
hyperpigmentation	I:C0333616
)	O
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	O
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	O
fluence	O
were	O
reported	O
.	O

Given	O
that	O
purpura	O
and	O
subsequent	O
possible	O
postinflammatory	O
hyperpigmentation	I:C0333616
(	O
postinflammatory	O
hyperpigmentation	I:C0333616
)	O
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	O
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	B:C0243095
fluence	O
were	O
reported	O
.	O

To	O
deliver	O
the	O
sufficient	O
high	O
fluence	O
of	O
a	O
PDL	B:C1289859
without	O
generating	O
purpura	O
,	O
we	O
designed	O
the	O
fractionation	O
of	O
high	O
fluence	O
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
(	O
6	O
milliseconds	O
)	O
of	O
a	O
PDL	O
in	O
succession	O
.	O

To	O
deliver	O
the	O
sufficient	O
high	O
fluence	O
of	O
a	O
PDL	O
without	O
generating	O
purpura	B:C0034150
,	O
we	O
designed	O
the	O
fractionation	O
of	O
high	O
fluence	O
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
(	O
6	O
milliseconds	O
)	O
of	O
a	O
PDL	O
in	O
succession	O
.	O

To	O
deliver	O
the	O
sufficient	O
high	O
fluence	O
of	O
a	O
PDL	O
without	O
generating	O
purpura	O
,	O
we	O
designed	O
the	O
fractionation	B:C3161031
of	O
high	O
fluence	O
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
(	O
6	O
milliseconds	O
)	O
of	O
a	O
PDL	O
in	O
succession	O
.	O

To	O
deliver	O
the	O
sufficient	O
high	O
fluence	O
of	O
a	O
PDL	O
without	O
generating	O
purpura	O
,	O
we	O
designed	O
the	O
fractionation	O
of	O
high	O
fluence	O
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
(	O
6	O
milliseconds	O
)	O
of	O
a	O
PDL	B:C1289859
in	O
succession	O
.	O

A	O
total	O
of	O
eight	O
patients	O
with	O
erythematotelangiectatic	B:C1449852
rosacea	I:C1449852
were	O
enrolled	O
in	O
this	O
study	O
;	O
all	O
patients	O
were	O
treated	O
with	O
PDL	O
10	O
times	O
at	O
2	O
-	O
week	O
intervals	O
.	O

A	O
total	O
of	O
eight	O
patients	O
with	O
erythematotelangiectatic	O
rosacea	I:C1449852
were	O
enrolled	O
in	O
this	O
study	O
;	O
all	O
patients	O
were	O
treated	O
with	O
PDL	B:C1289859
10	O
times	O
at	O
2	O
-	O
week	O
intervals	O
.	O

Erythema	B:C0041834
and	O
telangiectasia	O
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	O
using	O
the	O
digital	O
photographs	I:C3899375
.	O

Erythema	O
and	O
telangiectasia	B:C0039446
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	O
using	O
the	O
digital	O
photographs	I:C3899375
.	O

Erythema	O
and	O
telangiectasia	O
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	B:C0031831
using	O
the	O
digital	O
photographs	I:C3899375
.	O

Erythema	O
and	O
telangiectasia	O
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	O
using	O
the	O
digital	B:C3899375
photographs	I:C3899375
.	O

Moderate	O
-	O
to	O
-	O
marked	O
improvement	O
was	O
achieved	O
in	O
most	O
of	O
the	O
patients	O
,	O
and	O
erythema	B:C0041834
and	O
telangiectasia	O
scores	O
were	O
significantly	O
decreased	O
.	O

Moderate	O
-	O
to	O
-	O
marked	O
improvement	O
was	O
achieved	O
in	O
most	O
of	O
the	O
patients	O
,	O
and	O
erythema	O
and	O
telangiectasia	B:C0039446
scores	O
were	O
significantly	O
decreased	O
.	O

Purpura	B:C0034150
and	O
postinflammatory	O
hyperpigmentation	I:C0333616
were	O
not	O
reported	O
in	O
all	O
patients	O
.	O

Purpura	O
and	O
postinflammatory	B:C0333616
hyperpigmentation	I:C0333616
were	O
not	O
reported	O
in	O
all	O
patients	O
.	O

The	O
fractionation	B:C3161031
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
nm	O
PDL	O
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	O
for	O
erythematotelangiectatic	O
rosacea	I:C1449852
.	O

The	O
fractionation	O
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
nm	O
PDL	B:C1289859
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	O
for	O
erythematotelangiectatic	O
rosacea	I:C1449852
.	O

The	O
fractionation	O
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
nm	O
PDL	O
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	B:C0087111
for	O
erythematotelangiectatic	O
rosacea	I:C1449852
.	O

The	O
fractionation	O
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
nm	O
PDL	O
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	O
for	O
erythematotelangiectatic	B:C1449852
rosacea	I:C1449852
.	O

